Microbot Medical (MBOT) Stock Overview
A clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MBOT Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Microbot Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.05 |
| 52 Week High | US$4.67 |
| 52 Week Low | US$0.85 |
| Beta | 1.22 |
| 1 Month Change | 31.07% |
| 3 Month Change | 65.31% |
| 1 Year Change | 309.09% |
| 3 Year Change | -29.20% |
| 5 Year Change | -47.13% |
| Change since IPO | -97.33% |
Recent News & Updates
Microbot Medical: LIBERTY's Disposable Endovascular Robot Nears FDA Catalyst
Aug 28We're Not Very Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Rate
Jul 24
Recent updates
Microbot Medical: LIBERTY's Disposable Endovascular Robot Nears FDA Catalyst
Aug 28We're Not Very Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Rate
Jul 24Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?
Dec 30Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Invest In Growth?
Sep 01Here's Why We're A Bit Worried About Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation
Dec 28Microbot Medical acquires Nitiloop, terms undisclosed
Oct 07Here's Why We're Watching Microbot Medical's (NASDAQ:MBOT) Cash Burn Situation
Sep 13Microbot Medical confirms GLP trial on track to begin later this month
Sep 02Will Microbot Medical (NASDAQ:MBOT) Spend Its Cash Wisely?
Apr 23Microbot Medical's Stryker Collaboration Makes This An Intriguing High Flier
Jan 06Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth
Dec 24We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth
Aug 27Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth
May 12Shareholder Returns
| MBOT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 10.7% | -1.8% | 1.7% |
| 1Y | 309.1% | 0.6% | 18.7% |
Return vs Industry: MBOT exceeded the US Medical Equipment industry which returned 0.6% over the past year.
Return vs Market: MBOT exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| MBOT volatility | |
|---|---|
| MBOT Average Weekly Movement | 12.8% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MBOT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBOT's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 20 | Harel Gadot | microbotmedical.com |
Microbot Medical Inc., a clinical-stage medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the United States. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
Microbot Medical Inc. Fundamentals Summary
| MBOT fundamental statistics | |
|---|---|
| Market cap | US$212.91m |
| Earnings (TTM) | -US$12.71m |
| Revenue (TTM) | n/a |
Is MBOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBOT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.71m |
| Earnings | -US$12.71m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/14 14:45 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Microbot Medical Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |